MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response
MiR-152/PKM2/SLC7A5 轴在乳腺癌发展、化疗和放疗反应中的作用
基本信息
- 批准号:10445658
- 负责人:
- 金额:$ 64.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAlternative SplicingAmino AcidsAnimal ModelBiologyBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentCell LineCell modelCellsChemotherapy and/or radiationDNADNA MethylationDataDevelopmentDoxorubicinEndothelial CellsEstrogen receptor positiveFamilyFutureGoalsHNRPA3 geneHeterogeneous-Nuclear RibonucleoproteinsHomologous GeneHumanHypermethylationIL8 geneMalignant NeoplasmsMediatingMetabolicMethylationMicroRNAsModelingMolecularMusclePathway interactionsPlayPolypyrimidine Tract-Binding ProteinPromoter RegionsProtein IsoformsProtein KinaseProteinsPyruvate KinaseRadiationRadiation therapyResearch Project GrantsResistanceRoleSignal PathwayTestingTherapeuticTherapeutic procedureTissuesTumor AngiogenesisTumor TissueUp-RegulationWarburg EffectWomanangiogenesisbasecancer cellcancer survivalcancer therapychemoradiationcohortexperimental studyimprovedknock-downmalignant breast neoplasmmembermortalitymultidisciplinarynew therapeutic targetorthotopic breast canceroverexpressionparacrinepatient derived xenograft modelreceptorsolutetherapy resistanttranslational potentialtreatment responsetriple-negative invasive breast carcinomatumortumor growthtumor metabolism
项目摘要
Breast cancer (BCa) is the leading cause of women cancer mortality worldwide, and triple negative breast
cancer (TNBC) cells accounts for 15-20% BCa. However, higher therapeutic resistance and lower survival
of TNBC patients remain the major hinder of BCa treatment. Doxorubicin (Dox) and radiation are commonly
used for TNBC treatment. In our preliminary study, we found that TNBC showed much lower expression
levels of miR-152. Higher expression levels of zeste homologue 2 (EZH2) and DNA hypermethylation were
involved in miR-152 suppression in TNBC cells. To understand mechanism of miR-152 suppression, and
role and mechanism of miR-152 in regulating cancer development and Dox- and radiation-induced
resistance, we performed a lot of preliminary experiments to identify what molecules that were potential
miR-152 direct targets as well as that were upregulated in Dox-resistant TNBC or PDX tumor tissues. We
found that pyruvate kinase muscle 2 (PKM2), solute Carrier Family 7 Member 5 (SLC7A5), and
polypyrimidine tract-binding protein (PTBP1) as direct targets of miR-152 with potential ability to converse
Dox-mediated resistance. PKM2, SLC7A5 and PTBP1 levels were increased when miR-152 expression
was suppressed in TNBC cells and PDX model. We found that miR-152 suppression played an important
role in mediating TNBC metabolic reprogramming, Warburg effect switch, tumor growth and Dox resistance
through PKM2/SLC7A5/PTBP1. We showed that overexpression of miR-152 or PKM2 knockdown rendered
TNBC cells more sensitive to radiation treatment. These new findings create new opportunity to investigate
mechanism of TNBC therapeutic resistance. We hypothesize that resistance to chemotherapy and
radiation treatment, metabolic reprogramming, and TNBC development are induced by miR-152
suppression and upregulation of PKM2, SLC7A5, and PTBP1. To test this central hypothesis, we will
perform experiments through three aims. In Aim 1, we will investigate role and mechanism of miR-152
suppression in TNBC cells in doxorubicin- and radiation-induced resistance; and role and mechanism of
PKM2 switch and induction via alternative splicing by miR-152 suppression to induce Warburg effect,
therapeutic resistance, and tumor growth. In Aim 2, we will determine role and mechanism of miR-
152/SLC7A5/PTBP1 pathway in regulating metabolic reprogramming and Warburg effect switch, and in
mediating doxorubicin- and radiation-induced therapeutic resistance. In Aim 3, we will determine whether
miR-152 suppression and PKM2 induction regulate tumor angiogenesis through CXCL8 expression using a
humanized chimeric tumor model; and whether levels of miR-152, PKM2, HIF-1α, hnRNPA3, SLC7A5, and
PTBP1 are correlated each other, and are correlated with therapeutic responses and with the cancer stages
and survival. This R01 project will identify mechanisms of therapeutic resistance, and metabolic
reprogramming; and provide information for developing new treatment option of TNBC in the future.
乳腺癌(BCa)是全世界妇女癌症死亡的主要原因,三阴性乳腺癌
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jun He其他文献
Jun He的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jun He', 18)}}的其他基金
MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response
MiR-152/PKM2/SLC7A5 轴在乳腺癌发展、化疗和放疗反应中的作用
- 批准号:
10593136 - 财政年份:2022
- 资助金额:
$ 64.48万 - 项目类别:
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer
非小细胞肺癌EGFR-TKIs获得性耐药的新机制
- 批准号:
10098004 - 财政年份:2020
- 资助金额:
$ 64.48万 - 项目类别:
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer
非小细胞肺癌EGFR-TKIs获得性耐药的新机制
- 批准号:
10085027 - 财政年份:2020
- 资助金额:
$ 64.48万 - 项目类别:
New mechanisms of acquired resistance to EGFR-TKIs in Non-small-cell lung cancer
非小细胞肺癌EGFR-TKIs获得性耐药的新机制
- 批准号:
10328910 - 财政年份:2020
- 资助金额:
$ 64.48万 - 项目类别:
NOX4 Mediates Oxidative Stress in Ovarian Tumor growth and treatment Response
NOX4 介导卵巢肿瘤生长和治疗反应中的氧化应激
- 批准号:
10304003 - 财政年份:2015
- 资助金额:
$ 64.48万 - 项目类别:
相似海外基金
Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
- 批准号:
488788 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Operating Grants
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
- 批准号:
10577186 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
- 批准号:
10673458 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
- 批准号:
2884151 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
- 批准号:
10660668 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
- 批准号:
2239056 - 财政年份:2023
- 资助金额:
$ 64.48万 - 项目类别:
Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
- 批准号:
468851650 - 财政年份:2022
- 资助金额:
$ 64.48万 - 项目类别:
Research Grants